Alpha·methyl-para-tyrosine (AMPT), a tyrosine kydroxylase inhibitor, was used to evaluate the ylrysiologic role of central nervous system catecholamines 
In contrast, although combined treatment with AMPT and sleep deprivation led to large increases in negative mood, neither treatment alone produced consistent mood changes. These findings are consistent with the view that sleep deprivation is associated with decreased functional catecholamine neurotransmission. Furthermore, mood effects following sleep deprivation plus AMPT suggest that catecholamines may be involved in mood changes during sleep deprivation. £Neuropsychopharmacology 8:345-356, 1993J .
The restorative actions of amphetamine are thought to be secondary to functional increases in catecholamine neurotransrnission (Glowinski et al. 1966) . Conversely, drugs that decrease catecholamine activity also influ ence arousal. In general, drugs that inhibit noradrener gic or dopaminergic activity increase daytime sleepi ness. For example, a variety of catecholamine receptor blockers cause sedation, fatigue, and sleepiness (Betts 1981) and decrease sleep latency times (Nicholson and Pascoe 1990) .
Further evidence for catecholaminergic involve ment in arousal stems from clinical observations made in a variety of patient populations treated with alpha methyl-para-tyrosine (AMPT); AMPT is a selective cat echolamine synthesis inhibitor that can be utilized to determine the involvement of catecholamines in be havior (Nagatsu et al. 1964 ; Spector et al. 1965) . In pa tient populations, AMPT has been noted to produce sedation early in the course of treatment (Engelman et a1. 1968; Jonsson et a1. 1971; Ahlenius et al. 1973;  0893-133X/93/$0 .00 Pozuelo 1976; Nasrallah et al. 1977} . In addition, it has been noted that discontinuation of AMPT treatment is associated with insomnia and decreased total sleep (Bunney et al. 1971 (Bunney et al. , 1977 . This observed rebound in somnia has been postulated to be secondary to an in crease in catecholaminergic activity. Further evidence for catecholaminergic involvement in the sleep-wake cycle has been reviewed elsewhere (Mendelson 1987) . In addition to their importance in sleep, there is con siderable pharmacologic evidence that brain catechol amines are involved in the regulation of mood (Schild kraut 1965; Bunney and Davis 1965; Greenspan et al. 1969; Iqbal et al. 1989; Schildkraut et al. 1973a Schildkraut et al. , 1973b Goodwin and Post 1975) , although the relationship be tween sleep and mood is complex. For example, major depression is associated with objective electroen cephalographic sleep abnormalities (Kupfer and Thase 1983; Gillin 1983) , and manic patients typically have de creased sleep, particularly during the period when they switch into mania (Bunney et al. 1972) . Further suggest ing a link between the regulation of mood and arousal is the observation that the majority of depressed pa tients exhibit symptomatic improvement following one night of total sleep deprivation (Vogel et al. 1975) . The mechanism by which sleep deprivation improves mood in depressed individuals remains unclear, but may in volve catecholamines (Siegel and Rogawski 1988; Hart mann and Schildkraut 1973; Schildkraut et al. 1973b; Post et al. 1976; Mogilnicka et al. 1986) .
Despite the growing clinical interest in the relation ship between sleep and mood, few studies have reported on the effects of one night of sleep depriva tion on mood in healthy populations (Gerner et al. 1979; Gillberg and Akerstedt 1981) , and of these, results have varied. Moreover, no study that has investigated the effect of sleep deprivation on mood in normal volun teers has used a rested control group. The purpose of this study was twofold: frrst, to systematically evalu ate the effects of sleep deprivation on self-reported mood in healthy volunteers; and second, to use AMPT as a pharmacologic probe for assessing the role of cate cholamine neurotransmitters in changes of alertness and mood associated with sleep deprivation. The pres ent study was performed as part of a larger research project investigating the role of catecholamines in alert ness, sleep, performance, and mood.
METHODS

Subjects
Forty healthy men with a mean age of 25 years (range 21 to 36) were recruited through advertisements in lo cal newspapers. After an initial telephone screen, in terested volunteers came to the laboratory for a more detailed evaluation. After informed consent was ob- Figure 1 .
Drug Administration
Drugs were administered in a double-blind fashion, with subjects from both drug conditions included in each study run, beginning at 1430 hours on treatment day 1 (TD1). Subsequent doses were administered at 1830 and 2330 hours on TD1, and at 0730, 1330, 1830, and 2330 hours on treatment day 2 (TD2). Each of the seven doses contained 750 mg AMPT (or lactose pia· cebo), for a total of 5.25 g AMPT over a 33-hour period. Previous studies have shown that this regimen depletes cerebrospinal fluid catecholamines by 68% to 77% af· ter 24 hours . Subjects treated with AMPT in the present study had signiflcant elevations in serum prolactin concentrations on day 2, indicating depletion of eNS catecholamines at the level of the Ierp Deprivation PI!viously described methods for sleep-deprivation and paformance assessment were used, with minor mod btion (Newhouse et al. 1989 The next morning (TD1), subjects were in inn ed as to whether they had been randomized to the �deprived (no sleep for 43 hours) or rested (7 1/2 lwrs of sleep nightly) condition. Rested and sleep deprived study runs were conducted separately, both because of the logistics involved in running both sleep mnditions simultaneously, and because of possible con binding or adverse psychologic effects secondary to nmning both sleep conditions simultaneously (e.g. , it I possible that a subject who was required to remain .. ake while others were allowed to sleep would be Illre likely to report negative mood states). Sleep depri filion took place from 0700 hours on T01 until 2330 hours on TD2. All subjects slept from 2330 on TD2 un IiITlOO on recovery day (recovery sleep). During sleep deprivati on and during the day after recovery sleep, subjects took repeated measures of performance and mod. Additionally, subjects took modifIed Multiple Sleep Latency Tests (MSLTs; Carskadon and Dement
1982)
as an objective measure of sleepiness. During each lIOdif1ed MSLT, subjects were awakened as soon as they fell as leep (within 30 seconds), to maximize the eff ects of sleep deprivation. This study routine con tinued for sleep-deprived subjects at a slower pace dur iIg the time that rested subjects slept, to keep subjects II similar activity levels as during the day, and at the same time minimize the possibility that testing proce dures themselves would confound the data. During the two treatment days and recovery day, sleep-deprived subjects completed 25 WRAIR P ABs (rested subjects completed 21), 17 modifIed SLTs (rested subjects com pleted 15), and 13 visual analogue scales (VAS) (rested subjects completed 12). Rested subjects were not lWakened to collect data, and the data collected from sleep-d eprived subjects during the time that rested sub jects slept was not used in statistical comparisons. Data &om the cognitive tasks, sleep latency tests, and the Stan ford Sleepiness Scale (SSS) (Hoddes et al. 1973) has bee n reported elsewhere (McCann et al. 1992 ).
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Alertness and Mood Measures
Simultaneous measures of alertness and mood were taken during the two sleep-deprivation and drug treatment days (TD1 and TD2) and the day following recovery sleep (recovery day). Measurements included a pencil and paper VAS designed to measure global vigor and affect (Monk 1989) , and a computerized ver sion of the Prohle of Mood States ([POMS] McNair et al. 1971) which is incorporated into the WRAIR PAB. These measures were chosen because they have been validated in studies assessing mood changes in depressed patients and normal controls (Gillin et al. 1989; Wehr et al. 1985) , and because unlike the MSLT and SSS, these measures assess both alertness and mood scales using identical testing methods.
Visual Analogue Scale. All subjects completed three V AS questionnaires on TD1, four V AS questionnaires during T02, and four V AS questionnaires during recov ery day. Subjects were presented with eight questions, each pertaining to a particular mood. Below each ques tion was a 100-mm line on which they placed a mark indicating their self-rating on the mood in question at the time the questionnaire was administered. Labels at the two ends of the line indicated the opposite ex tremes of the mood. Mood scales on the V AS included alertness, sleepiness, weariness, effort required to com plete tasks, happiness, sadness, tension, and calmness. Possible scores ranged from 0 to 100.
Profile of Mood States. All subjects took fIVe POMS questionnaires during TD1, seven POMS question naires on TD2, and eight POMS questionnaires on recovery day. The POMS requires a subject to rate a level of agreement or disagreement to a list of 65 ad jectives or phrases. Mood scales on the POMS in clude Vigor-Activity (Vigor), Fatigue-Inertia (Fatigue), Depression-Dejection (Depression), Anger-Hostility (Anger), Tension-Anxiety (Tension), and Confusion Bewilderment (Confusion).
Data Analysis
A 2 (sleep condition: sleep-deprived/rested) x 2 (drug: AMPT/placebo) repeated-measures analysis of covari ance (ANCOVA) was used to evaluate the effects of AMPT administration and sleep deprivation on the alertness and mood scales of the POMS and V AS tests. Test scores in the morning (0800 to 1200 hours) of TD1, prior to drug administration, were used as covariates for the analyses of the above mentioned variables. Repeated-measures analyses were conducted sepa rately for the treatment phase of the experiment (T01 and TD2), and for recovery day. In cases where there was a signifIcant main effect of sleep condition or drug treatment, a sleep condition x drug treatment interac- NEUROPSYCHOPHARMACOLOGY 1993-VOL. 8, NO.1
RESULTS
Results from the overall repeated-measures ANCOVA during treatment days 1 to 2 and during recovery day are presented in Tables 1 and 2 
Measures of Alertness and Fatigue
Measures of Alertness. As shown in Fig. 2 , scoresof "alertness" from the V AS and "vigor" from the POMS indicate that: 1) during TD2, decreased alertness was observed due to both sleep deprivation and AMPT ad· ministration; 2) the effect of AMPT on alertness is more pronounced than the effect of sleep deprivation (e.g., the AMPT/R group differed signifIcantly from the P/SD group between 1200 of TD2 and 1200 of the recovery day in the VAS alertness scale); 3) AMPT plus sleep deprivation led to greater decreases in alertness than either treat ment alone; 4) the AMPT effect persisted during the recovery day; and 5) the effects of AMPT (II alertness are not observed until T02.
Mtuures of Sleepiness and Fatigue. As shown in Fig.   3 , scores of "sleepiness, " "weariness," and " effort" from !he VAS as well as scores of "fatigue" from the POMS (not shown in Fig. 3 ) indicate the following: 1) an in crease in fatigue was observed following both sleep deprivation and AMPT administration; 2) during T02, subjects in the AMPT/SO group had the highest scores on all of the sleepiness scales used; 3) on some scales
[Le., effo rt and sleepiness scales of the VAS) the effect rI AMPT per se was more pronounced than the effect rlsleep deprivation per se (i.e., signi&cant differences
were observed between the AMPT/R and P/SO groups during TD2 and recovery day on many of the data points); 4) the effects of AMPT on fatigue persisted af
Ier the ter mination of drug administration; and 5) no differen ce among the groups was observed during TD1.
Mood Measurements
Measures of Negative Mood. As shown in Fig. 4 and 5, scores of "sadness" and "tension" from the VAS, and scores of "tension," "depression," and " anger" from the POMS indicate that: 1) signihcant main effects of AMPT administration and sleep deprivation on negative mood scales observed in TD2 and recovery day are largely a reflection of high scores reported by the AMPT/SO group at most time points; 2) in both the AMPT IR group and the P/SO group, there was a trend for increases in negative mood that did not reach statistical signihcance, suggesting that for the short duration of this study, neither treatment alone was sufficient to al ter negative mood states in the subjects; and 3) drug effects on negative mood states may persist after the termination of the drug administration.
Measures of Positive Mood. As shown in Fig. 6 , scores on the "happiness" and "calmness" scales of the VAS
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Figure 2. Self-rated alertness using a VAS (Monk 1989 ) and vigor using the POMS (McNair et al. 1971 ). The numbers 1 and 2 denote signifIcant simple main effects (p < .01) of drug and sleep condition, respec tively, within an individual time point. The numbers 1* and 2* denote relevant near signifIcant simple main effects (p < .05) of drug and sleep con dition, respectively, with an in dividual time point.
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Figure 3. Self-rated sleepiness, wear iness, and effort required to complete a task using a V AS (Monk 1989) . The numbers 1 and 2 denote significant simple main effects (p < .01) of drug and sleep condition, respectively, within an individual time point. The numbers 1* and 2* denote relevant near significant simple main effects (p < .05) of drug and sleep condition, respectively, with an individual time point.
IIKlOd in healthy sleep-deprived individuals. In partic aIir, normal subjects treated with AMPT and subjected �40.5 hours of total sleep deprivation report increased dtpression, anger, confusion, tension, and anxiety, as well as decreased calmness and happiness. Interest q1y, treatment with AMPT or sleep deprivation alone led to onl y mild and inconsistent changes in mood. It was only when the two treatments were combined that ignibcant mood effects were observed, further suggesting that the two treatments interact with a common neu ral substrate (i.e., eNS catecholamines).
Although the effects of AMPT on mood in healthy individuals have not been previously reported, there have been observations on AMPT's effects in patient populations. In a study of 52 patients with a variety of medical conditions, it was noted that some patients de veloped an "anxiety state" (Engleman et al. 1968b ).
When given to unmedicated patients with bipolar aff ec-
.. o hours after the last AMPT dose, and dopamine levels reach control values 48 hours after the last AMPT dose (Rech et al. 1966 ). Second, it is possible that the combi nation of AMPT and sleep deprivation produced a general dysphoria, leading to a negative response bias w here all negative mood states were given high scores. Nevertheless, the fact that only the combination treat ment leads to dysphoria and the fInding that dysphoric mood parallels the time course of catecholamine deple tion, implicates catecholamines in the dysphoria pro duced during sleep deprivation. Third, although the actions of AMPT are specifIc to tyrosine hydroxylase (Nagatsu et al. 1964; Spector et al. 1965) , and thus do not directly influence metabolism of other neurotrans mitters, AMPT's actions on catecholaminergic systems could indirectly influence other neurotransmitters or neuropeptides (e.g., serotonin, acetylcholine, cholecys-
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11kinin, neuropeptide Y). As such, secondary changes lJother neurotransmitters and neuromodulators may i1Dbeinvolved in the AMP'T-induced changes in mood.
Although the relationship between mood and alert lU5iscomplex, evaluation of the effects of sleep depri mand AMPT in depressed patients could shed light tnlheextent of catecholamine involvement in the ther !plIdic effects of sleep deprivation. SpecifIcally, AMPT aid be used to test the hypothesis that the antidepres-
sant effect of sleep deprivation in depressed patients is related to changes in catecholamine neurotransmis sion (Siegel and Rogawski 1988) . For example, it has been postulated that downregulation of catecholamine neurotransmission caused by sleep deprivation (Stern and Morgane 1974; Mogilnicka et al. 1986; Radulovacki and Micovic 1983) leads to increased catecholamine turnover (Siegel and Rogawski 1988; Reisine 1981; Schildkraut and Hartmann 1972) , which in depressed Figure 6. Self-rated calmness and happiness using a VAS (Monk 1989 AMPT treatment would block mood improvements sec ondary to sleep deprivation. In summary, the present fmdings indicate that in healthy adults, treatment with sleep deprivation or AMPT produces sleepiness, and that combined treat ment with sleep deprivation and AMPT produces greater sleepiness than either treatment alone. In con trast, only combined treatment with AMPT plus sleep deprivation leads to marked increases in anxiety, depression, and anger, with either treatment alone producing only moderate and inconsistent mood changes. The observation that sleep deprivation and catecholamine depletion interact to influence alertness and mood is consistent with the view that catechol- amines play a role in alertness, and suggests that cate cholamine systems are involved in mood changes as sociated with sleep deprivation.
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